J A C C C A S E R E P O R T S V O L 4 N O 1 1 2 0 2 2 ª 2 0 2 2 T H E A U T H O R S P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R T H E C C B Y N C N D L I C E N S E h t t p c r e t v e c o m m o n s o r g l c e n s e s b y n c n d 4 0 CASE REPORT HEART CARE TEAMMULTIDISCIPLINARY TEAM LIVE Multidisciplinary Approach Hemodynamic Management During HighRisk Ventricular Tachycardia Ablation Aditya Bharadwaj MDa Melissa D McCabe MD MSCRb Tahmeed Contractor MDa Hyungjin Ben Kim DOa Antoine Sakr MDa Anthony Hilliard MDa Ravi Mandapati MDa Rahul Bhardwaj MDa ABSTRACT Percutaneous ventricular assist devices highrisk ventricular tachycardia ablation hemodynamic decompensation expected Utilizing case example present experience development coordinated teambased approach focused periprocedural management patients highrisk ventricular tachycardia Level Difﬁculty Advanced J Am Coll Cardiol Case Rep 20224639644 2022 The Authors Published Elsevier behalf American College Cardiology Foundation This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 tachycardia ablation VTA mias associated acute hemodynamic V entricular increasingly performed patients advanced heart failure1 Ablation quires induction mapping ventricular arrhyth LEARNING OBJECTIVES cid1 Acute hemodynamic decompensation occur ablation ventricular tachy cardia irrespective mappingablation strategy cid1 Objective measures cardiac function tissue perfusion assess efﬁcacy mechanical circulatory support guide weaning cid1 A multidisciplinary approach periproce dural hemodynamic management objective measures perfusion framework weaning mechanical support ensures best clinical outcome patient decompensation AHD Mechanical circulatory sup port MCS VTA increased observa tional studies PAINESD score suggest mortality beneﬁt2 The PAINESD score estimates risk AHD VTA Among patients noni schemic cardiomyopathy PAINESD score 15 MCS VTA decreased 30day rehospitalization repeat ablation recurrent implantable cardioverter deﬁbrillator ICD therapy 3month mortality3 Moreover prophylactic implementation MCS highrisk patients associated 35fold reduc tion mortality need heart transplantation45 Although evidence supports MCS highrisk VTA HRVTA pathways case selection pre procedural assessment multidisciplinary coor dination elucidated Currently established weaning protocols guide postprocedure care We present multidisciplinary approach HRVTA requiring MCS including rec ommendations weaning From aDivision Cardiology Department Medicine Loma Linda University Loma Linda California USA bDepartment Anesthesiology Loma Linda University Loma Linda California USA The authors attest compliance human studies committees animal welfare regulations authors institutions Food Drug Administration guidelines including patient consent appropriate For information visit Author Center Manuscript received October 19 2021 revised manuscript received February 1 2022 accepted February 22 2022 ISSN 26660849 httpsdoiorg101016jjaccas202202016 640 Bharadwaj et al HighRisk Ventricular Tachycardia Ablation J A C C C A S E R E P O R T S V O L 4 N O 1 1 2 0 2 2 J U N E 1 2 0 2 2 6 3 9 6 4 4 A B B R E V I A T I O N S A N D A C R O N Y M S AHD acute hemodynamic decompensation CPO cardiac power output HRVTA highrisk ventricular tachycardia ablation ICD implantable cardioverterdeﬁbrillator LV left ventricular MCS mechanical circulatory support pVAD percutaneous ventricular assist device SVO2 mixed venous oxygen saturation VT ventricular tachycardia VTA ventricular tachycardia ablation CASE PRESENTATION substratebased approach given recurrence VT 6 months ablation Preemptive MCS A 66yearold man heart failure percutaneous ventricular assist device pVAD reduced ejection fraction 2025 planned patient deemed high ischemic cardiomyopathy left ventricular risk PAINESD score 17 LV aneurysm history coronary ar tery bypass grafting mitral valve repair closure atrial septal defect presented evaluation ventricular tachycardia VT resulting appropriate ICD therapy He history VT storm treated catheter ablation substratebased approach extracorporeal membrane oxygenation support 5 months prior previously failed treatment amiodar sotalol dofetilide The patient pre sented multiple ICD shocks sustained monomorphic VT He evalu ated electrophysiology considered ANESTHESIA Before induction American Society Anesthesiologists monitors placed cerebral ox imetry initiated radial artery nulated General anesthesia induced etomidate succinylcholine followed endotra cheal intubation A pulmonary artery catheter placed right internal jugular vein Norepi nephrine epinephrine infusions titrated maintain blood pressure 20 baseline ce rebral saturation 60 20 baseline cardiac index 2 Lminm2 mixed venous oxygen saturation SVO2 60 cardiac power output CPO 06 W serum lactate 2 mmolL candidate repeat VT ablation pa tient preferred medical therapy He discharged sotalol readmitted 11 days later receiving 4 shocks monomorphic VT single morphology At point patient elected repeat catheter ablation A multidisciplinary conference electrophysi ology heart failure cardiologist interventional cardiologist cardiac anesthesiologist convened Electrophysiology recommended acti PERCUTANEOUS VENTRICULAR SUPPORT The right common femoral artery accessed ultra sound ﬂuoroscopic guidance angiography conﬁrmed position placement 6F sheath A pigtail catheter positioned abdominal aortic bifurcation angiogram performed evaluate signiﬁcant peripheral artery disease Heparin administered maintain activated clotting time 300 seconds The arteriotomy site progressively dilated placing 14F peelaway vation entrainment mapping strategy sheath The pigtail catheter advanced F I G U R E 1 Left Ventricular Mapping Clinical Ventricular Tachycardia A Left ventricular activation map clinical ventricular tachycardia B Left ventricular voltage map showing large anterior scar extending septum ablation lesions C Left bundle morphology superior axis precordial transition V5 positive lead I J A C C C A S E R E P O R T S V O L 4 N O 1 1 2 0 2 2 J U N E 1 2 0 2 2 6 3 9 6 4 4 Bharadwaj et al HighRisk Ventricular Tachycardia Ablation 641 F I G U R E 2 Left Ventricular Mapping Nonclinical Ventricular Tachycardia A Two views left ventricular activation map induced nonclinical ventricular tachycardia showing focal breakthrough anterior wall B Right bundle inferior axis negative lead I negative V2 V6 left ventricle pVAD placed resultant 38 Lmin ﬂow WEANING MCS AND POSTPROCEDURE CARE Post ablation CPO 09 W consistent baseline ABLATION Right femoral vein access obtained ultrasound guidance A long ﬁxed curve sheath perform transseptal puncture exchanged large curl deﬂectable sheath An irrigated forcesensing ablation catheter advanced sheath left ventricle A detailed bipolar voltage map left ventricle showed large anterior wall scar corresponding location aneurysm Figure 1 VT induced mapped multielectrode splined mapping activation map identiﬁed critical isthmusbased activation pattern presence catheter middiastolic potentials Ablation performed clinical VT longer inducible maintained pVAD weaned Auto P2 40 minutes On P2 arterial pulsatility preserved mean arterial pressure 70 mm Hg norepinephrine 3 mgkgmin SVO2 60 serum lactate 14 mmolL The pVAD removed hemostasis obtained suturebased closure devices The patient extubated care transferred cardiac intensive care unit norepinephrine weaned home heart failure medication regimen restarted He discharged home 2 days postablation At 1year followup remains free sustained VT required ICD therapy QUESTION 1 WHAT IS THE BENEFIT OF MCS targeted ablation Additional ablation performed DURING HRVTA scar core isolation approach Pacing high output conﬁrmed scar electrically unexcitable postablation MCS improves hemodynamics continuously loads left ventricle believe action Induction attempted scar homogeniza translates improved endorgan perfusion tion second morphologically distinct VT HRVTA Indeed cerebral desaturation induced An activation map left ventricle created cycle length tachycardia captured LV endocardium suggesting epicardial component circuit Figure 2 Additional ablation performed exit site based ﬁndings extensive endocardial ablation sustained nonclin activation map After ical VT epicardial component remained inducible initial clinical VT remained noninducible observed fast VT tachycardia cycle length 300 milliseconds MCS inci dence cerebral desaturation decreases signiﬁ cantly6 Prophylactic MCS superior rescue strategy 30day mortality higher rescue compared preemptive pVAD implantation highrisk patients experiencing AHD VTA7 Even successful rescue improved hemody namics 402 patients AHD VTA died 30 days8 Furthermore preemptive MCS 642 Bharadwaj et al HighRisk Ventricular Tachycardia Ablation J A C C C A S E R E P O R T S V O L 4 N O 1 1 2 0 2 2 J U N E 1 2 0 2 2 6 3 9 6 4 4 T A B L E 1 Multidisciplinary Periprocedural Care T A B L E 2 Best Practices Implant Explant MCS cid1 Case identiﬁed highrisk VTA requiring Vascular access hemodynamic support cid1 Determination PAINESD score assess ment current hemodynamics cid1 Ablation strategy mapping vs substrate Electrophysiologist ablation Ultrasound ﬂuoroscopyguided access Access micropuncture kit conﬁrmation femoral angiography Abdominal aortogram assess peripheral artery disease cid1 Discuss anticipated need delayed weaning cid1 Establish plan durable LVADheart trans plantation persistent hemodynamic support required cid1 Identify optimal access site femoral vs axillary cid1 Perform vascular access implant remove Impella device cid1 Assist weaning MCS Heart failure cardiologist Interventional cardiologist cid1 Preprocedure risk stratiﬁcation cid1 Hemodynamic monitoring ASA monitors arterial line PA catheter cerebral oximetry TEE evaluation endorgan perfusion cid1 Vasopressorinotrope management Cardiac anesthesiologist cid1 Postprocedure care cid1 Assist delayed weaning MCS cid1 Wean vasopressorsinotropes Cardiac intensivist ASA ¼ American Society Anesthesiologists LVAD ¼ left ventricular assist device MCS ¼ mechanical circulatory support PA ¼ pulmonary arterial TEE ¼ transesophageal echo cardiography VTA ¼ ventricular tachycardia ablation Intraprocedural monitoring Periodic assessment hematoma oozing sheath given prolonged nature VTA high ACTs 300 s Assessment distal limb perfusion recommend ipsilateral contralateral femorofemoral bypass case occlusive largebore sheath Closure Preclose technique recommended Contralateral femoral left radial arterial access dryclosure endovascular balloon tamponade especially patients increased bleeding risk longterm anticoagulation access site calciﬁcation vascular tortuosity andor large pannus Reversal anticoagulation protamine sulfate cases persistent bleeding ACT ¼ activated clotting time abbreviations Table 1 unload left ventricle The PAINESD score validated effective way risk stratify patients use objective perfusion measures provides additional guidance MCS warranted guide weaning QUESTION 2 WHAT IS THE APPROACH TO MULTIDISCIPLINARY CARE Multidisciplinary care dedicated VT unit favor ably affects VT recurrence hospitalization9 However multidisciplinary management HRVTA established Ideally HRVTA includes interdisciplinary expertise interventional car diology heart failure specialist cardiac anesthesi ologist occasionally cardiacvascular surgeon addition treating electrophysiologist Table 1 MCS implantation explantation performed experienced interventional cardiologist proﬁcient largebore best practices vascular access adheres Table 2 The interventionalist electrophysiolo gist coordinate timing MCS insertion need epicardial access The cardiac anesthe siologist critical role preprocedure planning reduce inotropic vasopressor usage avoid periprocedural hemodynamic management The associated myocardial oxygen demand impair anesthesiologist tasked maintaining end tissue perfusion This underscores ment importance preprocedure risk stratiﬁcation preemptive MCS Preemptive MCS organ perfusion presence recurrent VT AHD Figure 3 The heart failure cardiologist assists optimizing volume status considered irrespective VTA strategy activation procedure center heart failure medica entrainment techniques substrate tions typically held reduce periprocedural mapping precipitate AHD We prefer pVAD hypotension They assist weaning MCS ease placement ability provide postprocedure care instrumental J A C C C A S E R E P O R T S V O L 4 N O 1 1 2 0 2 2 J U N E 1 2 0 2 2 6 3 9 6 4 4 Bharadwaj et al HighRisk Ventricular Tachycardia Ablation 643 F I G U R E 3 Objective Assessment Tissue Perfusion F I G U R E 4 Weaning MCS Prolonged tachycardia hypotension provoke myocardial ischemia stunning increasing reliance mechanical circulatory support MCS We recommend assessment cardiac power output CPO pulsatility arterial waveform mixed venous oxygenation saturation SVO2 lactate decreasing device ﬂows We suggest reassessing weaning criteria reduction withdrawing MCS Maintenance endorgan perfusion induction QUESTION 3 WHAT PARAMETERS GUIDE ventricular tachycardia paramount We aim maintain car diac index 2 Lminm2 mixed venous oxygenation 60 cardiac power output 06 W lactate 2 mmolL blood pressure cerebral oximetry 60 90 20 baseline assessing candidacy advanced heart failure WEANING OF MCS During HRVTA monitor CPO objective mea sures endorgan perfusion Figure 3 perfusion delineates efﬁcacy MCS deﬁnes weaning criteria Figure 4 Weaning begins therapies When epicardial access planned assessment CPO important marker cardiothoracic surgery involved multi disciplinary care endorgan perfusion patients acute myocar dial infarction cardiogenic shock10 A CPO 06 W F I G U R E 5 Loss Intrinsic Arterial Pulsatility Hemodynamics percutaneous ventricular assist device console showing loss pulsatility native heart dependence chanical circulatory support 644 Bharadwaj et al HighRisk Ventricular Tachycardia Ablation J A C C C A S E R E P O R T S V O L 4 N O 1 1 2 0 2 2 J U N E 1 2 0 2 2 6 3 9 6 4 4 suggests adequate intrinsic cardiac function Next nation objective hemodynamic assessment This arterial waveform evaluated loss pulsa potentially paradigmshifting approach HRVTA tility indicates dependence MCS Figure 5 Pul signiﬁcant satility preserved vasopressor inotropic support A SVO2 60 lactate levels 2 mmolL suggest tissue perfusion adequate We suggest decreasing vice ﬂows reassessing weaning criteria withdrawing MCS Delayed weaning considered baseline LV ejection fraction 20 andor CPO 06 W In experience objective assessment perfusion helps avoid AHD MCS interrogated systematically evaluate clinical outcomes ACKNOWLEDGMENTS JetPub Scientiﬁc Communi cations LLC supported Abiomed assisted preparation paper accordance Good Publication Practice GPP3 guidelines FUNDING SUPPORT AND AUTHOR DISCLOSURES HRVTA MCS pa This work supported research funding Abiomed Dr rameters guide vasoactive support suggest Bharadwaj consultant speaker proctor Abiomed All ventricular arrhythmias terminated andor mapping discontinued CONCLUSIONS authors reported relationships relevant contents paper disclose ADDRESS FOR CORRESPONDENCE Dr Melissa D McCabe Loma Linda University Department Anes We present approach HRVTA MCS thesiology 11234 Anderson Street MC 2352 Loma Linda highlight importance multidisciplinary coordi California 92354 USA Email mmccabelluedu R E F E R E N C E S 1 Tzou WS Tung R Frankel DS et al Ventricular tachycardia ablation severe heart failure ventricular assist devices highrisk patients dergoing catheter ablation scarrelated ven ventricular international ablation center collaboration analysis Circ Arrhythm Elec trophysiol 201710 tachycardia 2 Mariani S Napp LC Lo Coco V et al Mechanical lifethreatening circulatory Int J Cardiol arrhythmia systematic review 20203084249 support tricular tachycardia propensityscore matched analysis Heart Rhythm 20181515001506 setting dedicated unit treatment complex longterm outcome ablation Circulation 2013127 13591368 arrhythmias ventricular 6 Miller MA Dukkipati SR Chinitz JS et al Percutaneous hemodynamic support Impella 25 scarrelated ventricular tachycardia ablation PERMIT 1 Circ Arrhythm Electrophysiol 20136151159 10 Basir MB Kapur NK Patel K et al Improved outcomes associated use shock pro tocols updates National Cardiogenic Interv Initiative Catheter Cardiovasc Shock 20199311731183 3 Aryana A Gearoid ONeill P Gregory D et al Procedural clinical outcomes catheter ablation unstable ventricular tachycardia sup ported percutaneous left ventricular assist device Heart Rhythm 20141111221130 4 Muser D Castro SA Liang JJ Santangeli P Identifying risk management acute hae modynamic decompensation catheter tachycardia Arrhythm ablation ventricular Electrophysiol Rev 20187282287 7 Mathuria N Wu G RojasDelgado F et al Outcomes preemptive rescue use percutaneous left ventricular assist device pa tients structural heart disease undergoing catheter tachycardia ablation ventricular J Interv Card Electrophysiol 2017482734 8 Kar B Gregoric ID Basra SS Idelchik GM Loyalka P The percutaneous ventricular assist device severe refractory cardiogenic shock J Am Coll Cardiol 201157688696 5 Muser D Liang JJ Castro SA et al Outcomes left prophylactic use percutaneous 9 Della Bella P Baratto F Tsiachris D et al Management ventricular tachycardia KEY WORDS ablation hemodynamics multidisciplinary care percutaneous mechanical circulatory support ventricular tachycardia Go httpwwwaccorg jaccjournalscme CMEMOCECME quiz article